Zhongfu Technology: Plans to acquire the controlling stake of Junke Zhengyuan (CRO), with an overall valuation of 1 billion yuan

Zhongfu Technology ( 300692.SZ ) Announced that the company’s wholly-owned subsidiary Dingfu Pharmaceutical plans to sign a “Framework Agreement on Equity Transfer” with Shanghai Jinpian, Shiguang Hengsheng, and others, to plan the acquisition of the national-level specialized and innovative “Little Giant” enterprise Junke Zhengyuan and its control of CRO assets. The estimated overall valuation of the target equity is 1 billion yuan, and after the transaction is completed, the target company will be included in the company’s consolidated financial statements. The agreement stipulates that Dingfu Pharmaceutical needs to pay no more than 30 million yuan as an acquisition earnest money. Regarding performance commitments, Junke Zhengyuan’s expected net profit attributable to non-recurring gains and losses from 2026 to 2028 is no less than 66 million yuan, 77 million yuan, and 88 million yuan, respectively. This transaction does not constitute an associated transaction or major asset restructuring, and the final plan is subject to audit evaluation and approval, with uncertainties.